Coverage
Filings
| Filing | Date |
|---|---|
| Additional dividend and bonus issue appr | 14 Sept 2004 |
| Also a bonus issue is proposed by the Bo | 24 Aug 2004 |
| 158,000 Orion A-shares converted into B- | 18 Aug 2004 |
| Orion to publish Interim Report 1-6/2004 | 9 Aug 2004 |
| Additional dividend of EUR 2.14 proposed | 9 Aug 2004 |
| Orion Group Interim Report 1-6/2004 | 9 Aug 2004 |
| 158,000 Orion A-shares converted into B- | 1 Jul 2004 |
| Orion Group Interim Report 1-3/2004 | 18 May 2004 |
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Announcement in accordance with section | 28 Apr 2004 |
| Profit warning: Orion?s Q1 operating pro | 15 Apr 2004 |
| Management change in Orion Pharma | 1 Apr 2004 |
| Orion?s new corporate name Orion Oyj reg | 1 Apr 2004 |